Cellosaurus logo
expasy logo

Cellosaurus BC-1 (CVCL_1079)

[Text version]
Cell line name BC-1
Synonyms BC1
Accession CVCL_1079
Resource Identification Initiative To cite this cell line use: BC-1 (RRID:CVCL_1079)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~35-48 hours (DSMZ=ACC-677).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
Omics: Array-based CGH.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
Cell type: B-cell; CL=CL_0000236.
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0.64
East Asian, North0.52
East Asian, South0
South Asian0.4
European, North67.92
European, South30.53
Disease Primary effusion lymphoma (NCIt: C6915)
Primary effusion lymphoma (ORDO: Orphanet_48686)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_4221 ! HBL-6
Sex of cell Male
Age at sampling 46Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2230; Cosmic-CLP=910919; DSMZ=ACC-677

Markers:
AmelogeninX,Y
CSF1PO10,11
D2S133819,23
D3S135814,15
D5S81811,12
D7S82011
D8S117914,16
D13S3178
D16S53912,13
D18S5112,15
D19S43313,14
D21S1128,30
FGA22,23
Penta D11
Penta E11,12
TH019.3
TPOX8,9
vWA16,20

Run an STR similarity search on this cell line
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=BC-1
Publications

PubMed=7670109; DOI=10.1182/blood.V86.7.2708.2708
Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M., Chang Y.
In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.
Blood 86:2708-2714(1995)

PubMed=8523568; DOI=10.1128/JVI.70.1.549-558.1996; PMCID=PMC189843
Moore P.S., Gao S.-J., Dominguez G., Cesarman E., Lungu O., Knowles D.M., Garber R., Pellett P.E., McGeoch D.J., Chang Y.
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.
J. Virol. 70:549-558(1996)

PubMed=9766492; DOI=10.1038/sj.leu.2401160
Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas).
Leukemia 12:1507-1517(1998)

Patent=US5908773
Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.
KSHV positive cell lines.
Patent number US5908773, 01-Jun-1999

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005; PMCID=PMC538532
Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
J. Virol. 79:1244-1251(2005)

PubMed=17121789; DOI=10.1128/JVI.01757-06; PMCID=PMC1797584
Burd C.E., Sin S.-H., Dittmer D.P.
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
J. Virol. 81:1912-1922(2007)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21685375; DOI=10.1182/blood-2010-12-323659; PMCID=PMC3158728
Roy D., Sin S.-H., Damania B., Dittmer D.P.
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.
Blood 118:e32-e39(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36094314; DOI=10.1128/JVI.00739-22; PMCID=PMC9517713
Ding W.-Y., Wang C., Narita Y., Wang H.-B., Leong M.M.L., Huang A., Liao Y.-F., Liu X.-F., Okuno Y., Kimura H., Gewurz B.E., Teng M.-X., Jin S.-L., Sato Y., Zhao B.
The Epstein-Barr virus enhancer interaction landscapes in virus-associated cancer cell lines.
J. Virol. 96:e00739.22.1-e00739.22.11(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2230
DSMZ; ACC-677
Cell line databases/resources CLO; CLO_0001887
cancercelllines; CVCL_1079
Cell_Model_Passport; SIDM00896
Cosmic-CLP; 910919
DepMap; ACH-002214
DSMZCellDive; ACC-677
IGRhCellID; BC1
LINCS_LDP; LCL-1956
Lonza; 914
Anatomy/cell type resources BTO; BTO:0002720
Biological sample resources BioSample; SAMN03471843
BioSample; SAMN03473432
BioSamples; SAMEA365796
BioSamples; SAMEA365808
Chemistry resources ChEMBL-Cells; CHEMBL3307907
ChEMBL-Targets; CHEMBL614277
GDSC; 910919
PharmacoDB; BC1_77_2019
PubChem_Cell_line; CVCL_1079
Encyclopedic resources Wikidata; Q54795185
Experimental variables resources EFO; EFO_0002044
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM33136
GEO; GSM38792
GEO; GSM38793
GEO; GSM634731
GEO; GSM710417
GEO; GSM710433
GEO; GSM1669610
GEO; GSM3150236
Polymorphism and mutation databases Cosmic; 687602
Cosmic; 910919
Cosmic; 1515186
Cosmic; 1588556
IARC_TP53; 21189
IARC_TP53; 23656
Progenetix; CVCL_1079
Proteomic databases PRIDE; PXD012087
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number40